Novo valuation surpasses Tesla on experimental obesity drug data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Rescue work underway after quakes rock Venezuela, 'high casualties' likely
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK1,054 at TD Cowen
March 11, 2024 2:03 PM EDTTD Cowen analyst Steve Scala raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK1,054.00 (from DKK925.00) while maintaining a Outperform rating.
The analyst comments "Novo announced FDA approval of the expanded label for Wegovy, now indicated to reduce CV risk in people with both obesity and CVD based on data from SELECT. Though these data are widely appreciated by specialists after... More
Jefferies starts Viking Therapeutics (VKTX) at buy on 'scarcity value'
March 7, 2024 1:59 PM ESTJefferies initiated Viking Therapeutics (NASDAQ: VKTX) with a Buy rating and $110 per share price target in a note Thursday, telling investors the company is a strong mid-stage obesity player with scarcity value.
VKTX is developing subQ/oral VK2735 (GLP-1/GIP) for obesity,... More
